Browsing by Author "Alizadegan, F."

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • No Thumbnail Available
    Publication
    Infliximab therapy in behcet's uveitis
    (Masson Editeur, 2022-10-20) Alizadegan, F.; Yalçınbayır, O.; Gündüz, G. Uçan; Pehlivan, Y.; PEHLİVAN, YAVUZ; YALÇINBAYIR, ÖZGÜR; 0000-0002-7311-5277; 0000-0002-5458-1686; IYJ-9408-2023; AAH-6661-2021
    Purpose. - To evaluate the efficacy of infliximab (IFX) therapy in patients with Behc , et's uveitis (BU) refractory to conventional immunomodulatory treatment (IMT).Materials and methods. - This study, trial registration number TCTR20200806007, included cases of BU with a minimum of 18 months follow-up on IFX treatment. Demographic char-acteristics, ophthalmological examination findings, control of ocular inflammation with IFX, response to treatment and the rate of clinical remission were analyzed in this study.Results. - Sixty-two eyes of 35 patients on IFX therapy were included in the study. The mean follow-up was 49.5 +/- 25.9 months. The mean frequency of recurrences during the IMT was 1.47 +/- 0.78 (attacks/year), decreasing to 0.31 +/- 0.40 (attacks/year) with IFX (P < 0.001). Visual acuity improved significantly in the 1st month of IFX treatment (P = 0.026). Partial response to treatment was achieved in 91.4% of cases.Conclusion. - IFX is a safe and effective treatment in cases of BU refractory to conventional IMT.